Cue Biopharma insider reports initial holdings
Cue Biopharma, Inc. filed an initial Form 3 showing that Chief Legal Compliance Officer and Corporate Secretary Ray Sumita holds 54,589 shares of common stock directly.
Rhea-AI Filing Summary
Cue Biopharma, Inc. filed an initial Form 3 showing that Chief Legal Compliance Officer and Corporate Secretary Ray Sumita holds 54,589 shares of common stock directly. The filing also reports a stock option covering 109,179 shares of common stock at an exercise price of $30.42 per share, expiring on May 1, 2036.
According to the footnote, this stock option becomes exercisable in equal quarterly installments over four years measured from May 1, 2026, meaning vesting is spread over that period rather than all at once.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Ray Sumita
Role
Chief Legal Compliance Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 109,179 contracts (Direct);
Common Stock — 54,589 shares (Direct)
Footnotes (1)
- F1. The stock option becomes exercisable in equal, quarterly installments over four years measured from May 1, 2026.
Key Figures
Direct common shares: 54,589 shares
Option underlying shares: 109,179 shares
Option exercise price: $30.42/share
+1 more
4 metrics
Direct common shares
54,589 shares
Common Stock held directly by Ray Sumita
Option underlying shares
109,179 shares
Underlying Common Stock for stock option
Option exercise price
$30.42/share
Exercise price for the stock option
Option expiration
May 1, 2036
Expiration date of the stock option
Key Terms
Form 3, Stock Option (Right to Buy, exercise price, expiration date, +1 more
5 terms
Form 3 regulatory
"Cue Biopharma, Inc. filed an initial Form 3 showing that..."
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Stock Option (Right to Buy financial
"The filing also reports a stock option covering 109,179 shares..."
exercise price financial
"at an exercise price of $30.42 per share, expiring on May 1, 2036."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"The option expires on May 1, 2036 and represents a right to buy shares..."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vests quarterly financial
"becomes exercisable in equal quarterly installments over four years..."
FAQ
What does Cue Biopharma (CUE) disclose in this Form 3 for Ray Sumita?
Cue Biopharma reports that Chief Legal Compliance Officer Ray Sumita holds 54,589 common shares and a stock option for 109,179 shares at $30.42. The option expires May 1, 2036 and vests quarterly over four years starting May 1, 2026.
What are the key terms of Ray Sumita’s stock options in Cue Biopharma (CUE)?
The filing lists a stock option for 109,179 Cue Biopharma common shares with a $30.42 exercise price per share. The option expires on May 1, 2036 and represents a right to buy shares if exercised under the vesting schedule described.
How do Ray Sumita’s Cue Biopharma (CUE) stock options vest?
The stock option becomes exercisable in equal quarterly installments over four years measured from May 1, 2026. This means portions of the 109,179 underlying shares become available to exercise each quarter until the full grant is vested over the four-year period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
